|
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)
|
|
W24-026-1
|
|
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)
|
|
Dr. Swarup Kumar
|
|
Teclistamab (also named JNJ-64007957) is an experimental medication being studied in this research study to see if it may be beneficial in the treatment of multiple myeloma. The purpose of this study is to see how teclistamab by itself compares to treatment combinations that are commonly used to treat multiple myeloma. These treatment combinations are either pomalidomide, bortezomib and dexamethasone (called PVd) or carfilzomib and dexamethasone (called Kd).
|
Cancer - General
|
|
|
Check with study contact
|
|
Maria Keane. Telephone: 860-679-1144. Email: mkeane@uchc.edu
|
|
Enrolling/recruiting.
|
|
|